Amgen Posts Stronger-than-Expected 3Q Results -- Earnings Review

Date : 10/29/2019 @ 8:48PM
Source : Dow Jones News
Stock : Amgen Inc (AMGN)
Quote : 222.95  -2.64 (-1.17%) @ 9:49PM
After Hours
Last Trade
Last $ 222.50 ▼ -0.45 (-0.20%)

Amgen Posts Stronger-than-Expected 3Q Results -- Earnings Review

Historical Stock Chart

3 Months : From Oct 2019 to Jan 2020

Click Here for more Amgen Charts.

By Maria Armental


Amgen Inc. (AMGN) reported third-quarter results on Tuesday and raised annual financial targets. Here's what you need to know:


PROFIT: Net income for the quarter ended Sept. 30 rose 6% to $1.97 billion, or $3.27 a share. On an adjusted basis, profit fell to $3.66 a share from $3.69 a share. Analysts surveyed by FactSet expected $3.19 a share and $3.53 a share as adjusted.


REVENUE: Total revenue fell 2.8% to $5.74 billion, compared with the consensus of $5.63 billion.


OUTLOOK: Amgen now expects $12.50 to $12.80 a share in profit, or $14.20 to $14.45 a share as adjusted, on $22.8 billion to $23 billion in revenue. Previously, it projected $12.10 to $12.71 a share, or $13.75 to $14.30 a share on an adjusted basis, and $22.4 billion to $22.9 billion in revenue. In 2018, it reported $12.62 a share, or $14.40 a share as adjusted, on $23.75 billion in revenue.


OTEZLA: The outlook doesn't include any potential impact from psoriasis medicine Otezla (apremilast), which Amgen agreed to buy from Celgene Corp. (CELG) in a roughly $13.4 billion deal that is expected to close by the end of the fourth quarter.


REPATHA: Sales of the cholesterol drug rose 40% in the latest period. Starting next year, Repatha (evolocumab) will list for $5,850 a year, about 60% lower than current price, to make the medicine more affordable to patients and kick-start sales.


ENBREL: Sales of Amgen's top-selling drug Enbrel (etanercept), which is at the center of a legal challenge that has kept competitors' biosimilar offerings at bay, rose 6% to $1.37 billion in the latest period. Analysts projected $1.26 billion in sales.


Write to Maria Armental at


(END) Dow Jones Newswires

October 29, 2019 16:33 ET (20:33 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Latest AMGN Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.